Site Map

Site Map
Home

Tutorials Inflammation

Cytokines

Systemic Enzymes

alpha-macroglobulin

Conditions

Benefits

Conditions

Alzheimer's Gout Prostatitis

Angina Hepatitis Psoriasis

Atherosclerosis Infertility Pyelonephritis

Autoimmune Thyroid Disease Kidney Stones Respiratory Tract Infections

Behcets Lymphedema Rheumatoid Arthritis

Diabetes Multiple Sclerosis Sports Medicine

Diabetic Nephropathy Myocardial Infarction Thrombophlebitis

Eczema Osteoaroarthritis Autoimmune Thyroid Disease

Fibrocystic Breast Pelvic Inflammatory Disease Urinary Tract Infections

Posters

Presentations

Articles

Testimonials
Read Testimonies
Read Dr. Collins Testimony
Share Your Testimony

Scientific Research

http://www.rcsb.org/pdb/home/home.do

http://www.chem.qmul.ac.uk/iubmb/enzyme/

Conformation and protease binding activity of binary and tertiary human alpha 2-macroglobulin-protease complexes.

Beta-amyloid peptide binds equivalently to binary and ternary alpha2-macroglobulin-protease complexes.

Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins.

Protease activation of alpha2-macroglobulin modulates a chaperone-like action with broad specificity.

Alpha 2-macroglobulin-mediated degradation of amyloid beta 1--42: a mechanism to enhance amyloid beta catabolism.

Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex.

alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein.

Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation.

Beta-amyloid peptide binds equivalently to binary and ternary alpha2-macroglobulin-protease complexes.

Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons.

Ligation of cell surface-associated glucose-regulated protein 78 by receptor-recognized forms of alpha 2-macroglobulin:activation of p21-activated protein kinase-2-dependent signaling in murine peritoneal macrophages.

In vitro binding and in vivo clearance of human alpha 2-macroglobulin after reaction with endoproteases from four different classes.

Efficacy of systemic enzyme therapy in the treatment of patients with chronic hepatitis B.

Lipoprotein Immune Complexes As Markers of Atherosclerosis Lipoprotein Immune Complexes As Markers of Atherosclerosis

Regular intake of Wobenzym® may prevent late complications in diabetes mellitus.

Systemic enzyme treatment as a method of secondary prevention in patients after myocardial infarction in the rehabilitation period.

Systemic Enzyme Therapy - Newest Status and Progress.

Systemic enzyme therapy in the treatment of neurodermitis (atopic dermatitis) patients.

Systemic enzyme therapy in the treatment of patients with myocardial infarction.

The Efficacy of Systemic Enzyme Therapy in the Treatment of Rheumatoid Arthritis.

The results of long-term use of Wobenzym in complex management of Behcet's disease.

Wobenzym in therapy of various forms of fibrocystic disease with individually selected immunomodulators.

Enzyme therapy in treatment of mastopathy.

Treatment of fibrocystic mastopathy with hydrolytic enzymes.

Systemic enzyme treatment as a method of secondary prevention in patients after myocardial infarction in the rehabilitation period.

Systemic enzyme therapy in the treatment of patients with myocardial infarction.

Strazhesko New approaches to modern cardiology based on systemic enzyme therapy.

Systemic enzyme therapy in the complex treatment of angina pectoris.

Clinico-laboratory evaluation of treatment efficacy in chronic pyelonephritis patients with Wobenzym.

Phlogenzym® in patients with relapsing urinary tract infections: Efficacy & Tolerance.

Coenzyme metabolic assurance of patients with recurrent nephrolithiasis in the complex treatment by systemic enzyme therapy.

Immunological aspects of systemic enzyme therapy (SET) in the complex treatment of recurrent nephrolithiasis.

Enzyme Therapy in Diabetic Nephropathy – Experimental and First Clinical Data.

Wobenzym® in the Treatment of Chronic Pelvic Inflammatory Disease.

Therapy of adnexitis - enhancement of the basic antibiotic therapy with hydrolytic enzymes.

Physical activity and immune system. Systemic enzyme therapy in prevention and treatment.

Diagnosis and treatment of lymphedema.

Systemic enzyme therapy and complex decongestive therapy in the patients with primary and secondary lymphedema of lower extremity.

Orally administered proteases in aesthetic surgery.

Proteolytic enzymes in lymphedema therapy.

Wobenzyme and diuretic therapy in lymphedema after breast operation.

Efficacy and tolerability of proteolytic enzymes as an anti-inflammatory agent in lymphoedema after axillary dissection due to mammary cancer.

Application of Wobenzym and Phlogenzym to the angiology and vascular surgery.

Systemic enzyme therapy of lower limb postphlebitic syndrome.

Wobenzym in the treatment of Thrombophlebitis.

Wobenzym® in the Treatment of Acute Thrombophlebitis.

Wobenzym in the complex treatment of autoimmune thyroiditis.

Systemic enzyme therapy in the treatment of children with recurrent infections of respiratory tract.

Therapeutic efficacy of Wobenzym in patients with focal pneumonia.

Use of oral enzymes in multiple sclerosis patients.

Wobenzym® and Wobe-Mugos® in the Treatment of Multiple Sclerosis.

Use of oral enzymes in multiple sclerosis: phenotyping of peripheral blood lymphocytes from MS patients under long-term treatment with orally administered hydrolytic enzymes.

Wobenzym in the treatment of patients with psoriasis.

Phlogenzym® in the Treatment of Chronic Prostatitis.

Efficacy and tolerance of oral enzyme therapy in chronic prostatitis: Results of a double-blind therapy study.

Special treatment of patients suffering from a mixed copulatory dysfunction with interoreceptive syndrome.

Immunomodulation in the treatment of reproduction disturbances.

Systemic enzyme therapy in the treatment of chronic salpingitis and infertility.

Enzyme therapy - a method of immune therapy for immunologically caused habitual abortion.

Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee--a double-blind prospective randomized study.

Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs.

Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: an open randomized controlled clinical trial.

Wobenzym in therapy of rheumatoid arthritis.

The results of long-term use of Wobenzym in complex management of rheumatoid arthritis.

The Efficacy of Systemic Enzyme Therapy in the Treatment of Rheumatoid Arthritis.

Pain Reduction in Rheumatic Diseases by Oral Therapy with Enzymes.

Our experience with Wobenzym in the treatment of patients with rheumatoid and psoriatic arthritis.

Clinical and immunological criteria of activity of different rheumatic arthritis courses and their treatment by Wobenzym.

New possibilities of basic therapy in patients with rheumatoid arthritis on the basis of systemic enzyme therapy.

Wogenzym(R) in teh Treatment of Patients with Juvenile Chronic Arthritis.

Using of systemic enzymotherapy for treatment of rheumatoid arthritis.

Our experience with Wobenzym in the treatment of patients with rheumatoid and psoriatic arthritis.

Basic treatment of rheumatoid arthritis: new approaches.

Systemic enzyme therapy in the gout treatment.

Prophylactic administration of Wobenzym to reduce consequences of sports injuries in karate fighters.

A double blind, randomised, parallel group study on the efficacy and safety of treating acute lateral ankle sprain with oral hydrolytic enzymes.

Physical activity and immune system. Systemic enzyme therapy in prevention and treatment.

Use of systemic enzyme therapy in the treatment of hand injuries and their consequences.

Search

FAQ (Frequently Asked Questions)

About Us

Contact Us

Terms of Use